Effects of ethanol and 5-HT1A agonists on astroglial S100B.
Previous studies from this and another laboratory demonstrated that in utero ethanol exposure reduces 5-HT neurons and S100B-immunopositive glia that are proximal to these neurons. Our laboratory also found that these effects are prevented by maternal treatment with a 5-HT(1A) agonist. Because of S100B's important role in the development of 5-HT neurons, the present study used both in vivo and in vitro models to investigate the potential involvement of S100B with the damaging effects of ethanol and with the protective effects of 5-HT(1A) agonists. We used in situ hybridization to address whether a 5-HT(1A) agonist could potentially affect S100B mRNA in vivo. Maternal treatment with buspirone between gestation days 13 and 20 significantly increased S100B mRNA in neuroepithelium of G20 offspring of control (40%) and ethanol-fed dams (20%). However, S100B mRNA was not altered in neuroepithelium from ethanol-exposed offspring. In astroglial cultures, we examined whether ethanol reduces the release of S100B and whether a 5-HT(1A) agonist could stimulate the release of this protein. We also evaluated the effects of ethanol and ipsapirone on astroglial content of S100B. Neither the concentration of S100B in astroglial media nor astroglial content of S100B were affected by ethanol. However, treatment with 100 nM ipsapirone, a 5-HT(1A) agonist, between the 6th and 7th day in vitro, increased astroglial release of S100B 2- to 3-fold. Thus, the protective effects of a 5-HT(1A) agonist on ethanol-treated 5-HT neurons might be associated with the ability of these drugs to release the neurotrophic factor S100B from astrocytes.
Eriksen
Jason L
JL
The Graduate Program in Neuroscience, Division of Molecular and Cellular Biochemistry, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA.
Gillespie
Roberta
R
Druse
Mary J
MJ
D020268:Alcohol-Induced Disorders, Nervous System / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D000818:Animals; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism; D002065:Buspirone / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D004195:Disease Models, Animal; D000431:Ethanol / Q000494:pharmacology*; D005260:Female; D005333:Fetus; D008297:Male; D009414:Nerve Growth Factors; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D011903:Raphe Nuclei / Q000187:drug effects* / Q000196:embryology* / Q000378:metabolism; D051381:Rats; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D044263:Receptors, Serotonin, 5-HT1; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000235:genetics*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013234:Stem Cells / Q000187:drug effects / Q000502:physiology
D009414:Nerve Growth Factors; D012333:RNA, Messenger; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579158:S100b protein, rat; D017366:Serotonin Receptor Agonists; D000431:Ethanol; D002065:Buspirone